6 news items
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DRRX
21 May 24
and potentially other indications. Actual results may differ materially from those contained in the forward-looking statements contained in this press release
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
DRRX
13 May 24
with AH and potentially other indications. Actual results may differ materially from those contained in the forward-looking statements contained
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DRRX
7 May 24
transplant in patients with AH and to save lives. Actual results may differ materially from those contained in the forward-looking statements
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
DRRX
30 Apr 24
larsucosterol for AH, MASH or other indications, and the potential benefits, if any, of our product candidates. Actual results may differ materially
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DRRX
27 Mar 24
benefits, if any, of our product candidates. Actual results may differ materially from those contained in the forward-looking statements contained
8rck4xhfwmz 295ewl0yctg7qnpcgj7naoxdytref0nj4mgwmna4
DRRX
20 Mar 24
transplant in patients with AH and to save lives. Actual results may differ materially from those contained in the forward-looking statements
- Prev
- 1
- Next